Abstract: Thyroid cancer is the most common malignant tumor in the endocrine system, which can be divided into follicular thyroid cancer, papillary thyroid cancer (PTC), medullary thyroid carcinoma and anaplastic thyroid carcinoma. Among them, PTC is the most common pathological subtype. At present, surgical resection, ¹³¹I therapy and thyroid hormone replacement inhibition therapy are considered as the best treatments for PTC, but a small part of patients will undergo tumor recurrence or metastasis and their 10 years survival rate will be significantly reduced by 40% ~ 85%. Different clinical pathological features, such as lymph node metastasis, extrathyroid invasion, TNM stage will cause different prognosises (recurrence, metastasis, death, etc.). Therefore, the clinicopathological features above are also used to predict the prognosis of patients with PTC, and identifying such risk factors as soon as possible will buy more time for appropriate intervention and treatment to improve the prognosis. This paper reviews the relationship between BRAF^V600E mutation and the clinicopathological features above and clinical poor prognosis of patients with PTC.